Macrophage dysfunction in the pathogenesis and treatment of asthma

被引:126
作者
Fricker, Michael [1 ]
Gibson, Peter G. [1 ,2 ]
机构
[1] Univ Newcastle, NHMRC Ctr Excellence Severe Asthma, Hunter Med Res Inst, Prior Res Ctr Hlth Lungs, Newcastle, NSW, Australia
[2] John Hunter Hosp, Dept Resp & Sleep Med, Newcastle, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
HUMAN ALVEOLAR MACROPHAGES; OBSTRUCTIVE PULMONARY-DISEASE; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; BRONCHIAL EPITHELIAL-CELLS; LEUKOTRIENE B-4 PRODUCTION; MESSENGER-RNA EXPRESSION; POORLY CONTROLLED ASTHMA; LOW-DOSE THEOPHYLLINE; INHALED CORTICOSTEROIDS;
D O I
10.1183/13993003.00196-2017
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Asthma is a chronic respiratory condition frequently associated with aberrant airway and systemic inflammation. Various inflammatory phenotypes in asthmatic airways have been described that relate to clinical phenotypes and impact on responses to conventional and novel asthma therapies. Macrophages are abundant immunocytes in the lung, capable of mounting diverse responses required for homeostasis and defence against pathogens. Here, we summarise the clinical evidence regarding macrophage dysfunction in asthma. We also describe evidence supporting the role of macrophages as therapeutic targets in asthma. We conclude that macrophage dysfunction in asthma is highly prevalent and heterogeneous, and hypothesise that macrophages may play roles in promoting the discrete inflammatory phenotypes of asthma. These clinical findings, along with recent ground-breaking insights into the ontogeny, behavioural complexity and longevity of pulmonary macrophages, support continued research into the role of macrophages as disease modifiers, biomarkers and therapeutic targets in asthma.
引用
收藏
页数:16
相关论文
共 179 条
  • [1] DETECTION OF CYTOKINES AND THEIR CELL SOURCES IN BRONCHIAL BIOPSY SPECIMENS FROM ASTHMATIC-PATIENTS - RELATIONSHIP TO ATOPIC STATUS, SYMPTOMS, AND LEVEL OF AIRWAY HYPERRESPONSIVENESS
    ACKERMAN, V
    MARINI, M
    VITTORI, E
    BELLINI, A
    VASSALI, G
    MATTOLI, S
    [J]. CHEST, 1994, 105 (03) : 687 - 696
  • [2] Treatable traits: toward precision medicine of chronic airway diseases
    Agusti, Alvar
    Bel, Elisabeth
    Thomas, Mike
    Vogelmeier, Claus
    Brusselle, Guy
    Holgate, Stephen
    Humbert, Marc
    Jones, Paul
    Gibson, Peter G.
    Vestbo, Jorgen
    Beasley, Richard
    Pavord, Ian D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (02) : 410 - 419
  • [3] Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369
  • [4] Biomarker sampling of the airways in asthma
    Alexis, Neil E.
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2014, 20 (01) : 46 - 52
  • [5] Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers
    Aubert, JD
    Juillerat-Jeanneret, L
    Fioroni, P
    Dayer, P
    Plan, PA
    Leuenberger, P
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 1998, 11 (04) : 263 - 269
  • [6] Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples
    Baines, Katherine J.
    Simpson, Jodie L.
    Wood, Lisa G.
    Scott, Rodney J.
    Gibson, Peter G.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (01) : 153 - U251
  • [7] BALDWIN DR, 1990, EUR RESPIR J, V3, P886
  • [8] Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge
    Balloy, V.
    Deveaux, A.
    Lebeaux, D.
    Tabary, O.
    le Rouzic, P.
    Ghigo, J. M.
    Busson, P. F.
    Boelle, P. Y.
    Guez, J. Guez
    Hahn, U.
    Clement, A.
    Chignard, M.
    Corvol, H.
    Burnet, M.
    Guillot, L.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (07) : 1783 - 1794
  • [9] Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors
    Banner, KH
    Page, CP
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1996, 26 : 2 - 9
  • [10] How corticosteroids control inflammation: Quintiles prize lecture 2005
    Barnes, Peter J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (03) : 245 - 254